Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bridging the Gap Between Value and Affordability

By Drug Discovery Trends Editor | June 2, 2015

Today’s biopharma industry faces more in-market risks than ever before. These include payment reforms such as bundled payments and limited global health care budgets. The industry must also manage greater provider financial risk for outcomes and resource use, as well as payer consolidation and new insurance designs that shift more costs to patients. And this is just the tip of the iceberg.  In this environment, the stakes are high. Identifying and communicating the value proposition of innovative products is nothing less than critical.

Traditionally, the biopharma industry has addressed these risks by speaking to the value of its innovations.  Increasingly, however, that value analysis is not resonating with payers, providers, and even patients.  They are shifting the discussion, changing the dialogue, and altering the debate. Rather than speaking of “the value of innovation,” these stakeholders are criticizing the cost (price) of drugs and are concerned about affordability.

Unquestionably, affordability is a huge issue that must be addressed – but it is really step two. Step one is the need to get the value question right.  It is clear that simply developing products to meet scientifically-defined “unmet medical need” is not sufficient in today’s markets.  

At a recent meeting of the International Society for Pharmacoeconomics and Outcomes Research, Penny Mohr of the U.S. Patient Centered Outcomes Research Institute said, “The health care industry needs a more crystal clear understanding of the factors important to patients, clinicians, and health systems.” 

I couldn’t agree more. Innovators need a clearer view of the innovations that are important to key therapeutic stakeholders, such as helping providers meet their performance metrics or improving patient quality of life. They need that knowledge well before product launch.  And they need to bring to market innovations that reflect and integrate those views. 

Perhaps the most important views in the evolving markets are those of the patient.  In the United States, and increasingly in other markets around the world, even insured patients are paying more out of pocket for healthcare goods and services.  If a product is not valued by the patient, market access could be more difficult than it would otherwise be. 

Signs of difficult market access are everywhere:

  • Significant use of formulary utilization management – prior authorization, step therapy, and tiering
  • Non-coverage of one or more branded products in crowded therapeutic classes
  • News headlines decrying the price of innovations

All these and other market access barriers stem in large part from the lack of payer and even, patient acceptance of a product’s value proposition. 

So where does that put us? A continued cycle of contention and missed opportunities for alignment? Hopefully not. Patients and their families in the United States and around the world need and deserve better.  And pharmaceutical companies need to be clearer in the value their products bring and what drives product price.  To achieve this, companies need a process that takes complex market dynamics into account – and they need to do this as early as possible. 

While certainly not complete, here’s a beginning check list to move us in a more positive, collaborative direction. Industry must start:

  • Gathering stakeholder views and opinions and evaluating what really matters to them;
  • Assessing policy trends in various markets and identifying their impact; and
  • Integrating the analyzed information into the research and development process.  

Only with this type of “environmental assessment” can companies really begin to understand what is at stake, what matters most to decision makers and how to communicate in ways that reflect values that are important to stakeholders outside of their own organization.  

READ MORE: 3 Ways Technology is Changing the Face of Drug Discovery & Development

While the value proposition and product price/cost are not synonymous, they are highly related. Increasingly, value is likely to be measured against costs to the patient, costs to the health care system, impact on a provider’s performance metrics and potentially even the provider’s payments. That’s a whole new set of considerations, and those also need to be subjected to a rigorous analysis and testing process 

While a strong value proposition will not resolve the issue of affordability, it is the foundation for maximizing market access.   Importantly, it will build a much-needed bridge to addressing the affordability of these important therapies.

Jane Horvath is the Market Access Lead for 3D Communications, which is a strategic communications firm that prepares pharmaceutical and device companies for high-stakes regulatory, payer, and other stakeholder interactions. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE